Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
References (20)
- et al.
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Biochem. Biophys Res. Commun.
(1997) - et al.
Correlations of synaptic markers with cognitive status in prospectively studied elderly humans
Neurobiol. Aging
(1995) - et al.
The `Mini mental state': a practical method for grading the cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975) Tau protein and the neurofibrillary pathology of Alzheimer's disease
Trends Neurol. Sci.
(1993)- et al.
Molecular characterization of microtubule-associated proteins tau and MAP2
Trends Neurosci.
(1991) - et al.
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study
J. Neurol. Neurosurg. Psychiatry
(1998) - et al.
Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease
Ann. Neurol.
(1995) - et al.
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease?
Mol. Chem. Neuropathol.
(1995) - et al.
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
Neurology
(1997) - et al.
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Nature
(1998)
Cited by (150)
Boosting the sensitivity for tau protein detection with a bifunctional nanoenzyme signal amplifier
2024, Sensors and Actuators B: ChemicalThe potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies
2021, Brain, Behavior, and Immunity - HealthCitation Excerpt :pT217 has also been detected in the blood plasma and shows promising and exciting results to be used as a new biomarker to test for preclinical stage AD (Palmqvist et al., 2020). When considering other tauopathies, such as FTD-17, there are discrepancies in the literature, with some studies reporting an elevation in CSF tau (Green et al., 1999), whilst others show no elevation in levels of tau in the CSF, but rather a possible increase in ISF tau (Grossman et al., 2005), potentially due to the nature of FTD being remote from ventricular CSF spaces in early stages of degeneration (Riemenschneider et al., 2002). Although this discrepancy suggests variability in CSF levels of tau, it is evident that tau can be secreted by neurons and found within the extracellular space, in either the ISF or CSF, under both normal physiological conditions and in disease states.
Salivary biological biomarkers for Alzheimer's disease
2019, Archives of Oral BiologyCitation Excerpt :As to the T-tau, a moderate to marked increase of CSF T-tau in AD or MCI that later progresses to AD with dementia has been found in numerous studies (Blennow & Hampel, 2003). However, high CSF T-tau levels will be found in a range of neurodegenerative disorders, such as Creutzfeldt- Jakob disease and some cases of frontotemporal dementia, proving that CSF T-tau is not specific for AD(Green, Harvey, Thompson, & Rossor, 1999; Otto et al., 1997). The specificity of CSF P-tau to differentiate AD from other dementias seems to be higher than T-tau; studies suggest that p-tau in CSF is not simply a marker for neuronal degeneration, but that it specifically reflects the phosphorylation state of tau and thus possibly the formation of tangles in brain of AD patients.
Postoperative Cognitive Dysfunction
2016, Complications in NeuroanesthesiaMTor mediates tau localization and secretion: Implication for Alzheimer's disease
2015, Biochimica et Biophysica Acta - Molecular Cell ResearchCerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease
2015, Journal of the Neurological Sciences